A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma. Fehniger TA, Watkins MP, Ezenwajiaku N, Wan F, et al. Haematologica 2023 Sep 14. doi: 10.3324/haematol.2022.282246.

Read + Share

Amedeo Smart

Independent Medical Education

Fehniger TA, Watkins MP, Ezenwajiaku N, Wan F, et al. A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma. Haematologica 2023 Sep 14. doi: 10.3324/haematol.2022.282246.
PMID: 37706336